HTDS - Hard to Treat Diseases, Inc. (OTCBB Stock)

[WeatherCat]

This thing has taken flight with HUGE volume and there's merger talk with a China Bio-Medical company...

Latest Press Release

Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China
Wednesday January 14, 2009, 8:22 am EST
Yahoo! Buzz Print SHENZHEN, China, Jan. 14 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) Welcome to the HTDS Medical Website management representatives are currently in China negotiating a merger agreement with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope).

Mellow Hope is the biggest exporter of Biological Vaccines in China, and has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.

Mellow Hope revenues are currently in excess of $15 million USD, and growing.

Interim company CEO Keith Roberts noted "We think there are going to be strong synergies between our European division and Mellow Hope. Mellow Hope brings a substantial pharmaceutical production and testing capability to the forefront of the Company. In turn, HTDS can provide vital and meaningful assistance to Mellow Hope in developing its export business to Europe and beyond".

Based on initial negotiations, the company anticipates having a formal Letter of Intent in place within a week to ten days, and will provide additional updates on developments as they unfold.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001@gmail.com; For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com

EmailIM Bookmarkdel.icio.usDigg Yahoo! Buzz
Top Stories
New jobless claims increase more than expected - AP
US mulls fresh aid package for Bank of America - AP
House Democrats propose $825 billion stimulus bill - AP
Stocks extend declines as bank worries persist - AP
JPMorgan posts profit, but 'disappointing' one - AP
Provided By
View more from provider »
ADVERTISEMENT


Tech Ticker Recent Posts
Nocera: JPMorgan's Profit Good for the Market, But Citi 'Going to Be a Bloodbath' - Aaron Task
Why You Shouldn't Be Investing in Stocks - Sarah Lacy
Who Cares If Facebook Is Worth $15B or $500M? - Sarah Lacy
View More »
Subscribe to Topics
Top Stories

[WeatherCat]

She ran hard today on massive volume...We could gap up in the morning with the merger talk ongoing. Up over 122% today and a couple of blocks at 0.0085 went through Atfer Hours...ME LIKEE!!!!!!!!!!!

[paperchase]

Hard To Treat Diseases (HTDS) Clinical Trial Update on Therapeutic effects of Combined Treatment With Ribavirin And Tiazofurin
1:48p ET July 1, 2009 (PR NewsWire)
Hard To Treat Diseases (HTDS) (HTDS Medical) Chief Scientist with its Slavica BioChem subsidiary, Dr. Sanja Pekovic provided updates on recent clinical trials with animal subjects in regards to the use of Ribavirin And Tiazofurin for the potential treatment of Multiple Sclerosis (MS).

Dr. Pekovic reported; "It is now well accepted that axonal injury begins at an early stage in MS, and likely accounts for clinical progression seen later in the disease course, suggesting that early, aggressive treatment is critical in order to suppress long-term disability progression. Researchers from IBISS group (a related research group) tested the effect of combined treatment with ribavirin (R) and tiazofurin (T) administrated during the effecter phase of disease.

Dr. Pekovic added: "We are hopeful, that with additional funding, we will be able to continue along this promising path, and continue researching the potential applications of a combination of ribavirin and tiazofurin in the treatment of MS."

This is a narrative report - release. A full detailed release will be posted on the company's website HTDS Medical shortly.

[paperchase]

Hard To Treat Diseases (HTDS.PK) Reasserting Multi Million Dollar IP Ownership Rights
1:22p ET July 9, 2009 (PR NewsWire)
Hard to Treat Diseases (HTDS.PK) HTDS Medical - announced today and as previously released on June 24, 2009, the Company is in the process of reasserting its ownership rights to certain intellectual property, which was inappropriately converted by the previous management of HTDS. 100% of the ownership rights are expected to be assigned back to HTDS. The following SEC filing INTERNATIONAL FOAM SOLUTIONS INC (Form: 10KSB40, Received: 06/02/2000 16:08:49) dated June 2, 2000 together with the activities of certain X employees and the aforementioned technology is the scope of the IP ownership rights and benefits'.

The IP rights are being utilized by a fully reporting OTCBB publicly traded company. As a result of HTDS IP rights, this company has raised over $14 million in equity financing, constructed an operating plant that generates revenue, is in the process of purchasing parcels of property in various States in order to construct additional plants and has had numerous industrial bonds approved for an average amount of $10 million each.

Once the rights have been reasserted by HTDS, various projections (based on confidential financial documents and projections of the OTCBB company) indicates gross revenue exceeding $250 million, gross profit exceeding $220 million and net income exceeding $40 million within two years.

HTDS management will decide the direction of the IP division shortly after the ownership rights have been finalized.

In other corporate news, the company advises its readers and followers that this IP ownership legal issue is separate and in addition to the partial distribution HTDS is entitled to as a beneficiary recipient in a slander lawsuit vs Investorshub.Com recently awarded in a Canada court proceeding. See link for details. Mina Mar Group - Protecting Our Client Interests

Additionally, HTDS will shortly be posting a legal opinion on its Adequate Disclosure Documents filed with Pink Sheets on June 2, 2009, in aid of obtaining a "Current Issuer" ranking.

The company will provide further details as they become available.

[paperchase]

Hard To Treat Diseases (HTDS.PK) Completes India Order
12:00p ET July 10, 2009 (PR NewsWire)
Hard to Treat Diseases (HTDS.PK) HTDS Medical - announced today that the second batch of Hepatitis A Vaccine of 2009 was delivered to India, by the company.

This is the second completed batch exported to India this year by the company. The first batch was delivered to India in March.

In summary, many people are recommended to receive Hepatitis A vaccine, including people at increased risk for exposure to HAV infection and people who are more likely to get seriously ill if infected with HAV. According to CDC recommendations, people who should be vaccinated include:

- All children at age 1 year (12-23 months) - People age 12 months or older who are traveling to or working in an area of the world except the United States, Canada, Western Europe, Japan, New Zealand, and Australia - Men who have sex with men - Users of illegal drugs, both oral and injecting - People who have blood clotting disorders - People who work with HAV-infected primates or with HAV in a research laboratory setting (no other groups have been shown to be at increased risk for HAV infection because of occupational exposure) - People with chronic liver disease - Any person who wishes to be immune to Hepatitis A

More about of Hepatitis A Vaccine can be found on this World Health Organization link Hepatitis A vaccine

[paperchase]

Hard To Treat Diseases (HTDS.PK) Agreement With 2nd Largest Vaccine Manufacturer in China Yunnan Walvax Biotech Co
11:32a ET July 13, 2009 (PR NewsWire)
Hard to Treat Diseases (HTDS.PK) HTDS Medical - subsidiary, Mellow Hope signed an agreement with Yunnan Walvax Biotech Co., Ltd for the Haemophilus influenza type b conjugate vaccine. Yunnan Walvax Biotech Co. Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China. This agreement / arrangement now sets the stage for Mellow Hope to be fully authorized to conduct the international marketing of Haemophilus influenza type b conjugate vaccine in the global market.

In other corporate news, the company plans on commencing the registration in Chile, Indonesia, Egypt, and Russia within this month with the brand name "MEVAC-Hib".

The company will provide further details as they become available.

[paperchase]

Hard To Treat Diseases (HTDS.PK) Tender Order To Indonesia
1:18p ET July 15, 2009 (PR NewsWire)
Hard to Treat Diseases (HTDS.PK) HTDS Medical announced today that the company is now preparing for the tender business of 250,000 doses of MEVAC-ACYW in Indonesia.

The product specifications and details can be viewed by visiting this web page directly Shenzhen Mellow Hope Pharm Industrial Co., Ltd..

This is the second completed batch exported to Indonesia this year by the company. The first batch was delivered to Indonesia in December 2008. At that time, the company successfully exported 70,000 doses of the product to Indonesia. Mr. Terry Yan CEO of HTDS said "The positive feedback of our product will help us to win the tender again this year. Our European division Slavica Bio Chem continues with its research and we are hopeful to release some further details of their work shortly."

[paperchase]

Hard To Treat Diseases (HTDS.PK) Thailand Registration
1:15p ET July 21, 2009 (PR NewsWire)
Hard to Treat Diseases (HTDS.PK) HTDS Medical announced today its intent to complete the registration of MEVAC-A for the country of Thailand. The registration is expected to be finished within the 3rd quarter of 2009.

This registration is required to accommodate a customer from Thailand, who has expressed interest in is Mellow Hope products such as MEVAC-A, MEVAC-DTaP, and MEVAC-ACYW.

Mellow Hope's Hepatitis A Vaccine is sold under the brand name MEVAC-A.

In total, the Company is in the process of registration, and clinical trials in countries of Southeast Asia, Latin America and Eastern Europe.

[paperchase]

Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatment for MS
11:16a ET July 23, 2009 (PR NewsWire)
Hard to Treat Diseases, Inc. (HTDS:PK) HTDS Medical reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sclerosis (MS).

The research team has been conducting experiments using Dark Agouti rats. Experimental autoimmune encephalomyelitis (EAE) induced in susceptible strains of animals provides the best available model for studying events in MS and a helpful tool in preclinical testing of various substances considered for treatment of the central nervous system (CNS) disease. CNS is the part of the nervous system that functions to coordinate the activity of all parts of the bodies of multicellular organisms.

In summary, these findings suggest that Ribavirin attenuates experimental autoimmune encephalomyelitis (animal model of multiple sclerosis) by limiting cytokine-mediated immuno-inflammatory events that lead to CNS destruction.

The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.

The aforementioned report will be posted shortly on the HTDS corporate web site HTDS Medical and on Pink Sheets under the tab "FILINGS" - Supplemental Information. Pink Sheets | Quotes, Company Info, Filings, News, Short Interest - Hard to Treat Diseases, Inc. - HTDS

Dr.Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem said "We are proud to be part of the Hard to Treat Diseases and we are grateful for the funding our division has received. This is of great assistance for continuing of our experiments. We have already ordered some chemicals and antibodies with the funding received. This has afforded us an opportunity to straighten our equipment and to introduce a new methodological approaches and techniques (like PCR and RT-PCR) that would give added value to our research".

Mr. Terry Yuan CEO said, "There is great synergy between the two companies Slavica BioChem and Mellow Hope. Although Slavica currently has no revenues, their developmental and research contributions have the potential to transform into enormous and massive gains for HTDS and its shareholders. We expect to be releasing HTDS Q2 financials shortly, and some positive updates on the IP issue very shortly. (see press release July 9, 2009 /PRNewswire-FirstCall via COMTEX/ for further details)"

[paperchase]

Hard to Treat Diseases (HTDS) To Re Release European TV Segment In N. America For Potential Treatment Of MS
7:00a ET July 28, 2009 (PR NewsWire)
Hard to Treat Diseases, Inc. (HTDS:PK) HTDS Medical, Slavica Bio Chem Division (Slavica) intends to re release a TV feature on the work of the medical team in the area of potential treatment of MS. The TV feature was aired in Europe only, several years ago.

Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer explains: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. All of us were talking about our work, our results, our lab was also presented. Also, there were some short movies about MS. It was very good and they repeated it several times on TV." Currently the company is in the process of obtaining translations and writing to the Director of RTS (TV) and intends to post the interview on its corporate web sites www.slavicabiotech.com and HTDS Medical. The company intends to make use of other media ie CD/DVD and similar to distribute the content to other medical professionals, research organizations, and companies in the medical industry to shed additional spotlight on the work of the Slavica Bio Tech team.

In other company news, within the next few weeks Slavica Bio Tech division intends to conduct a web cast only to address the work of Slavica. Dr.Sanja Pekovic, added: "Considering the potential, the exposure, and the spotlight this interview may bring to the company we are grateful and it is our pleasure, to have Professor Rakic (See Biography Link) (http://www.sanu.ac.rs/English/Clanst...bisavRakic.pdf ) accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and Ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the Serbian Academy of Sciences and Arts in charge for natural sciences."

Company followers are advised that a similar and a second web cast is being planned to feature only the Mellow Hope (HTDS China Subsidiary Vaccine Division) Shenzhen Mellow Hope Pharm Industrial Co., Ltd.. This second webcast will be chaired by the HTDS CEO, Mr. Terry Yuan.

Dr Pekovic concluded: "We are eager to get the message out to the industry on the work that our team is doing at Slavica. By that we mean not only to our shareholders but to the medical industry as well. We believe that our work is invaluable, that we have made some significant strides, which simply cannot be ignored and we believe that the market is just starting to take notice of our potential. To that end we have hired a liaison contact person, Dr. Ivana Gadjanski. Ivana comes highly qualified to us. She is a PhD. She has recently returned from Germany where she finished her PhD studies and got her PhD diploma, and now is a part of our team. Also, she is an assistant professor at the State University Novi Pazar, she speaks: English -professionally, CAE certificate, grades A, German - upper intermediate level, French - basics and is an enthusiastic young scientist with a lot of fresh and original ideas.

In our team she is responsible for introducing stem cell therapy in our models of EAE/MS and traumatic brain injury. Her duties will also include sending regular updates of our work to our North American office, the head office in China, and having our North American office and our advisors disseminate timely updates to the HTDS followers, shareholders and the medical professionals."

The company intends to provide many updates on the work and HTDS activities on a timely basis.